Genentech and PeptiDream to co-develop radiopharmaceuticals in $1BN deal
The Roche-owned U.S. giant Genentech has teamed up with the Japanese biotech Peptidream to co-develop peptide-based radiopharmaceutical treatments.
Stay updated with breaking news from Peptide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Roche-owned U.S. giant Genentech has teamed up with the Japanese biotech Peptidream to co-develop peptide-based radiopharmaceutical treatments.
Dublin, Aug. 30, 2023 (GLOBE NEWSWIRE) -- The "Global Peptide Therapeutics Market (2023-2028) by Synthesis Technology, Drug Class, Route of...
A European program has been researching how the pharmaceutical industry could use the peptides found in venomous creatures for new therapeutic medicines.
Hers! another personal best, another crowninu hers! another personal best, another crowning glory- _ hers! another personal best, another crowning glory. i've _ hers! another personal best, another crowning glory. i've committed - hers! another personal best, another crowning glory. i've committed to - crowning glory. i've committed to the vision. _ crowning glory. i've committed to the vision, i've _ crowning glory. i've committed to the vision, i've committed - crowning glory. i've committed to the vision, i've committed to - crowning glory. i've committed to i the vision, i've committed to ...
Research highlights the dual role of peptide YY, a gut hormone known for appetite control, is also serving as an immune regulator.